

**TABLE 206: PRURITUS**

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-2	1a, 1b	(6) SOF12 + LDV12	5	109	5%
		(10) SOF12 + LDV12 + RBV12	10	111	9%
		(7) SOF24 + LDV24	2	109	2%
		(11) SOF24 + LDV24 + RBV24	10	111	9%
Andreone et al., 2014 PEARL-II	1b	(14) PAR/RIT12 + OMB12 + DAS12	8	95	8%
Bourlière et al., 2015 SIRIUS	1	(7) SOF24 + LDV24	7	77	9%
		(10) SOF12 + LDV12 + RBV12	22	78	28%
Gane et al., 2013-2 ELECTRON	1a,b	(3) SOF12 + RBV12	2	10	20%
Gane et al., 2014-2 ELECTRON	1a,b	(10) SOF12 + LDV12 + RBV12	0	9	0%
Gane et al., 2014-3 ELECTRON	1a,b	(10) SOF12 + LDV12 + RBV12	0	9	0%
Forns et al., 2014 PROMISE	1	(1) PR48	37	133	28%
		(42) SIM12 PR24-48 RGT	72	260	28%
Jacobson et al., 2013 FUSION	2+3	(3) SOF12 + RBV12	12	103	12%
Jensen et al., 2015 HALLMARK-QUAD	1+4	(18) DCV24 + ASU24 + PR24	104	398	26%
Lawitz et al., 2014 LONESTAR	1a, 1b	(6) SOF12 + LDV12	1	19	5%
		(10) SOF12 + LDV12 + RBV12	0	21	0%
Lawitz et al., 2014 COSMOS	1a, 1b	(5) SIM12 + SOF12	2	14	14%
		(72) SOF12 + SIM12 + RBV12	2	27	7%
Lawitz et al., 2015-2 C-WORTHY	1	(57) GRZ12 + ELB12(50 mg q.d.)	2	33	6%
		(59) GRZ18 + ELB18(50 mg q.d.)	1	32	3%
		(63) GRZ12 + ELB12(50 mg q.d.) + RBV12	0	32	0%
		(65) GRZ18 + ELB18(50 mg q.d.) + RBV18	10	33	30%
Lok et al., 2014 DUAL A2	1b	(17) DCV24 + ASU24	1	20	5%
Lok et al., 2014 QUAD B2	1a, 1b	(18) DCV24 + ASU24 + PR24	8	21	38%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	14	205	7%
Osinusi et al., 2014 SYNERGY	1a, 1b	(6) SOF12 + LDV12	0	14	0%
Pol et al., 2015	1	(40) SOF12 + PR12	12	80	15%
Reddy et al., 2015 ATTAIN	1	(39) T12 PR48 q8	170	384	44%
		(68) SIM12 PR48	122	379	32%
Sulkowski et al., 2014-3	2+3	(4) SOF24 + RBV24	2	41	5%
Wyles et al., 2015	1	(10) SOF12 + LDV12 + RBV12	3	51	6%
Zeuzem et al., 2014 SAPPHIRE-II	1a, 1b	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	41	297	14%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Zeuzem et al., 2011 REALIZE	1	(1) PR48	36	132	27%
		(39) T12 PR48 q8	138	266	52%
Zeuzem et al., 2014 ASPIRE	1	(1) PR48	11	66	17%
		(68) SIM12 PR48	20	66	30%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q.d. = once daily; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.